id: NEW:metabolomic_predictive_biomarkers_to_sud_medication_treatment_rate_oud
name: Metabolomic Predictive Biomarkers for Treatment Response â†’ SUD Medication Treatment Rate
from_node:
  node_id: NEW:metabolomic_predictive_biomarkers
  node_name: Metabolomic Predictive Biomarkers for Treatment Response
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: SUD Medication Treatment Rate
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Metabolomic profiling identifies biomarkers that predict response to acamprosate'
- 'Step 2: Predictive biomarkers enable identification of patients likely to benefit from specific pharmacotherapy'
- 'Step 3: Treatment matching based on biomarkers improves medication effectiveness'
- 'Step 4: Improved treatment outcomes may increase retention and success rates in medication-assisted
  treatment'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'Shaunna L. Clark et al. 2024. "Next-generation biomarkers for alcohol consumption
    and alcohol use disorder diagnosis, prognosis, and treatment: A critical review.." https://doi.org/10.1111/acer.15476'
  supporting_citations:
  - Additional citations require full-text access - this is a critical review summarizing omics-based
    biomarker research
  - Studies on predictive biomarkers for acamprosate response referenced in review
  - Studies on metabolomic biomarkers in AUD treatment referenced in review
  doi: 10.1111/acer.15476
  citation_verified: true
  needs_manual_review: true
  citation_issues:
  - Primary citation doesn't match verified citation from literature search
last_updated: '2025-12-06'
version: '2.0'
description: Metabolomic biomarkers can predict response to acamprosate treatment in subjects with AUD,
  enabling personalized treatment approaches that match patients to therapies most likely to benefit them.
moderators:
- name: access_to_biomarker_testing
  direction: strengthens
  strength: moderate
  description: Availability of advanced metabolomic testing determines whether predictive biomarkers can
    be clinically utilized
- name: treatment_facility_capacity
  direction: strengthens
  strength: moderate
  description: Sufficient treatment infrastructure is needed to implement personalized treatment approaches
structural_competency:
  equity_implications: Implementation of predictive biomarkers requires structural changes in healthcare
    delivery. Equity concerns include whether advanced biomarker testing will be available to all populations
    or only those with resources. Insurance coverage policies, healthcare facility capabilities, and workforce
    training are structural factors determining who benefits from precision medicine advances in AUD treatment.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.738711'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
